SE441753B - SET TO MAKE A PROTECTED POLYPEPTIME WITH Diminished Prone to Immunization and Behavioral Physiological Activity - Google Patents

SET TO MAKE A PROTECTED POLYPEPTIME WITH Diminished Prone to Immunization and Behavioral Physiological Activity

Info

Publication number
SE441753B
SE441753B SE7409366A SE7409366A SE441753B SE 441753 B SE441753 B SE 441753B SE 7409366 A SE7409366 A SE 7409366A SE 7409366 A SE7409366 A SE 7409366A SE 441753 B SE441753 B SE 441753B
Authority
SE
Sweden
Prior art keywords
physiological activity
polypeptime
immunization
diminished
prone
Prior art date
Application number
SE7409366A
Other languages
Swedish (sv)
Other versions
SE7409366L (en
Inventor
F F Davis
Es T Van
N C Palczuk
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Publication of SE7409366L publication Critical patent/SE7409366L/xx
Publication of SE441753B publication Critical patent/SE441753B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for suppressing the immunogenic action of a biocatalyst which has a large number of peptide linkages, with at least partial retention of its physiological activity, entails attaching polymers to the biocatalyst; the biocatalyst is attached to a virtually linear polyalkyl or polyalkoxy polymer via at least one terminal carbon atom thereof; the polyalkyl or polyalkoxy polymer is unsubstituted or substituted by an alkoxy or alkyl group containing fewer than 5 C atoms.
SE7409366A 1973-07-20 1974-07-18 SET TO MAKE A PROTECTED POLYPEPTIME WITH Diminished Prone to Immunization and Behavioral Physiological Activity SE441753B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38119173A 1973-07-20 1973-07-20

Publications (2)

Publication Number Publication Date
SE7409366L SE7409366L (en) 1975-01-21
SE441753B true SE441753B (en) 1985-11-04

Family

ID=23504063

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7409366A SE441753B (en) 1973-07-20 1974-07-18 SET TO MAKE A PROTECTED POLYPEPTIME WITH Diminished Prone to Immunization and Behavioral Physiological Activity

Country Status (9)

Country Link
JP (1) JPS5623587B2 (en)
CA (1) CA1033673A (en)
CH (1) CH616942A5 (en)
DE (1) DE2433883C2 (en)
FR (1) FR2313939A1 (en)
GB (1) GB1469472A (en)
IL (1) IL45291A0 (en)
NL (1) NL7409770A (en)
SE (1) SE441753B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930542A1 (en) * 1979-07-27 1981-02-12 Hoechst Ag NEW INSULINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION
JPS58145691U (en) * 1982-03-29 1983-09-30 株式会社タイト− table type video game machine
JPS5976288U (en) * 1982-11-15 1984-05-23 大平技研工業株式会社 table type video game machine
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
JPS59204130A (en) * 1983-04-30 1984-11-19 Nippon Chemiphar Co Ltd Oral administration drug containing novel plasminogen activator derivative
DE3334407A1 (en) * 1983-09-23 1985-04-04 Hoechst Ag, 6230 Frankfurt INSULINE DERIVATIVES MODIFIED IN POSITION B 30, METHOD FOR THE PRODUCTION AND USE THEREOF AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF THE DIABETES MELLITUS
JPH0327674Y2 (en) * 1984-10-02 1991-06-14
JPS61163687U (en) * 1985-03-28 1986-10-09
JPS62207485A (en) * 1986-03-07 1987-09-11 大平技研工業株式会社 Television game machine
US5037969A (en) * 1986-07-03 1991-08-06 Takeda Chemical Industries, Ltd. Glycosyl derivatives and use thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5578496A (en) * 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
JP5020451B2 (en) * 1999-09-10 2012-09-05 ザ プロクター アンド ギャンブル カンパニー Enzyme inhibitor
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
CN102180944A (en) * 2001-10-10 2011-09-14 诺和诺德公司 Remodeling and glycoconjugation of peptides
MXPA04003597A (en) 2001-10-18 2004-07-30 Nektar Therapeutics Al Corp Polymer conjugates of opioid antagonists.
AU2003241279A1 (en) * 2002-03-26 2003-10-13 Biosynexus Incorporated Antimicrobial polymer conjugates
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1553993B1 (en) * 2002-10-21 2016-03-30 Allvivo, Inc. Surface coating comprising bioactive compound
EP1676862B1 (en) 2003-09-24 2010-12-22 Kyowa Hakko Kirin Co., Ltd. Recombinant antibody against human insulin-like growth factor
WO2005056636A2 (en) 2003-12-03 2005-06-23 Nektar Therapeutics Al, Corporation Method of preparing maleimide functionalized polymers
US20090042790A1 (en) * 2005-06-13 2009-02-12 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US10046058B2 (en) * 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
US20170342211A1 (en) * 2016-05-31 2017-11-30 Robert Bosch Gmbh Azlactone functionalized substrates for conjugation of biomolecules
MX2018014916A (en) * 2016-06-01 2019-07-18 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (en) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
US3674767A (en) * 1967-07-14 1972-07-04 Nat Res Dev Novel polymeric materials containing triazinyl groups

Also Published As

Publication number Publication date
NL7409770A (en) 1975-01-22
GB1469472A (en) 1977-04-06
FR2313939B1 (en) 1979-05-18
IL45291A0 (en) 1974-10-22
DE2433883C2 (en) 1986-03-27
JPS5623587B2 (en) 1981-06-01
DE2433883A1 (en) 1976-02-05
CH616942A5 (en) 1980-04-30
SE7409366L (en) 1975-01-21
JPS5042087A (en) 1975-04-16
CA1033673A (en) 1978-06-27
FR2313939A1 (en) 1977-01-07

Similar Documents

Publication Publication Date Title
SE441753B (en) SET TO MAKE A PROTECTED POLYPEPTIME WITH Diminished Prone to Immunization and Behavioral Physiological Activity
KR840002414A (en) Method for producing acrylic copolymer given amino function
JPS51139842A (en) Stabilizer for synthetic polymeric material
DE68916198D1 (en) Carbamoyl-2-pyrrolidinone compounds.
ES441678A1 (en) Polymerizates of olefinic nitriles
ES413926A1 (en) 2,2,2-trichloro-4'-tert butyl-acetophenone
GR3018529T3 (en) Nematode vaccine.
ES449430A1 (en) Certain 2,3-dihydrobenzofuranyl esters of certain N-sulfenylated carbamic acids
ES460621A1 (en) N-(1-allyl-2-pyrrolidylmethyl)-2,3-dimethoxy-5-sulfamoylbenzamide and derivatives thereof and method for treating hot flushes associated with natural or surgical menopause
DE3273145D1 (en) Virus vaccines and process for preparing the same
ES452391A1 (en) Benzisothiazoline-1,1-dioxide derivatives, compositions and methods
JPS5518409A (en) Preparation of polyurethane elastomer
FR2425429A1 (en) N-CYANO-AZOMETHINES USED FOR THE PREPARATION OF ANTIHISTAMINICS AND THEIR PREPARATION
SE7613536L (en) METHODS OF PREPARING 3,4-DISUBSTITUTED 2- (BETA-NAPHTYL-OXI) -ETHYLPYRAZOLONES AND THEIR USE AS MEDICINES
ES394637A1 (en) Vinyl esters polymers containing hindered phenolic groups
JPS53147059A (en) Brominated cyclic ether having alkoxycarbonyl group and its preparation
JPS5424869A (en) Heterocyclic compounds and their preparation
JPS5340719A (en) Organophosphorus compound and chlorine-containing resin composition
JPS55154918A (en) Carcinostatic
SU593451A1 (en) METHOD FOR STABILIZATION
ES457416A1 (en) A procedure for the preparation of poly (tetrametileneter) glicol. (Machine-translation by Google Translate, not legally binding)
ES384868A1 (en) A procedure for the preparation of pharmacodyamically active derivatives of hydroxyalcohylpiperazine. (Machine-translation by Google Translate, not legally binding)
ES420004A1 (en) Nitrosourea derivatives
ES289006A1 (en) Procedure for the preparation of stabilized polymers (Machine-translation by Google Translate, not legally binding)
ES440767A2 (en) Phenylethylamine derivatives

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7409366-7

Effective date: 19940810

Format of ref document f/p: F